Mohs Micrographic Surgery

at the Skin and Cancer Foundation Australia, 20 Years Later (1997–2017) BACKGROUND The availability of Mohs micrographic surgery (MMS) in Australia has increased dramatically since its inception in the 1980s. OBJECTIVE This study aimed to describe the evolution of MMS practices at the Skin and Cancer Foundation Australia (SCFA) over the past 20 years (1997–2017). METHODS Retrospective analysis of Mohs surgery cases at SCFA in 2017, 2007, and 1997, comparing data on sex, age, tumor type and site, initial tumor and final defect size, number of surgical stages and sections, and closure management. The present study is limited by being a retrospective analysis from a single institution. RESULTS There was a 415% increase in the number of Mohs surgery cases from 1997 to 2017, and a significant increase in Mohs surgery-treated squamous cell carcinoma. The preoperative tumor and final defect size have decreased. More side-to-side closures and fewer grafts are being performed over time. LIMITATIONS Retrospective analysis from a single institution. CONCLUSION Over the last 20 years, MMS has remained appropriate in its application and is being increasingly used for treatment of squamous cell carcinoma suggesting improved access. Address correspondence and reprint requests to: Thomas J. Stewart, BBioMedSc, MBBS, MMed, FRACGP, The Skin & Cancer Foundation Australia, 121 Crown Street Darlinghurst, Sydney, Australia, 2010, or e-mail: thomas_stewart@live.com The authors have indicated no significant interest with commercial supporters. © 2019 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.